Skip to main content
. 2020 Jan 28;10(2):226. doi: 10.3390/nano10020226

Figure 6.

Figure 6

Vascular homing peptide induced tissue-selective vasodilation in pulmonary arterial hypertension (PAH). (A) Vascular homing and cell penetrating peptide CAR homes to pulmonary arteries in disease-specific fashion in experimental models of PAH [27,28]. A little bit of control peptide (mutant CAR peptide) binding can be seen to similar blood vessel in PAH. (B) Effect of CAR (0.3 mg/kg) and Rho-kinase inhibitor Y27632 (1 mg/kg) mixture on right ventricle (RVSP, right ventricle systolic pressure) and left ventricle (SAP, systemic arterial pressure) systolic pressure in PAH. The CAR/Y27632 combination treatment induced a marked pulmonary-specific vasodilation RVSP with only a minimum effect on SAP in PAH. (C) Schematic presentation of the “bystander effect”, i.e. target organ-specific drug delivery, in PAH. Reproduced from [28] with permission from Elsevier 2017.